Brief: Aptinyx Presents Additional Positive Data From Phase 2 Exploratory Study Of NYX-783 In PTSD At Society Of Biological Psychiatry Annual Meeting
29/04/2021 12:48
April 29 (Reuters) - Aptinyx Inc APTX.O :
* APTINYX PRESENTS ADDITIONAL POSITIVE DATA FROM PHASE 2
EXPLORATORY STUDY OF NYX-783 IN PTSD AT SOCIETY OF BIOLOGICAL
PSYCHIATRY ANNUAL MEETING
Source text for Eikon: ID:nBw3srMQLa
Further company coverage: APTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptinyx
See all newsBrief: Aptinyx Gets Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Aptinyx Inc reports On May 4, Board Deemed It In Best Interests Of Co And Its Stockholders That Co Be Dissolved
Aptinyx Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aptinyx Inc Reports Quarterly Loss Per Share Of $0.18
Aptinyx Inc expected to post a loss of 19 cents a share - Earnings Preview